Anatabine Citrate: the most powerful anti-inflammatory ever
We need to be careful here. I think the operative phrase should be: "ANATABLOC IS THE MOST POWERFUL anti-inflammatory available without a prescription required AND WITH NO KNOWN SIDE EFFECTS."
I was on a very powerful Corticosteroid anti-inflammatory back in 2010 for 14 days before anatabine citrate was publicly available. It was called Methylprednisolone. That stuff was unbelievably good at shutting down the inflammation that was causing me so much discomfort in my back.
But if you take Methylprednisolone (or any other corticosteroid) as a long term solution, you run the risk of all sorts of serious medical problems.
BOTTOM LINE: In addition to shutting down "low-grade" inflammation, people who suffer some form of injury or other trauma are able turn to Anatabloc after initially taking Corticosteroids and find that Anatabloc is an excellent long term pain reduction solution for them.
People who take Anatabloc DO NOT have to worry about this long list of side effects:
Side effects of methylprednisolone: oral tablet Other dosage forms: injection powder for solution, injection suspension.
Along with its needed effects, methylprednisolone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking methylprednisolone:
More common Aggression agitation anxiety blurred vision decrease in the amount of urine dizziness fast, slow, pounding, or irregular heartbeat or pulse headache irritability mental depression mood changes nervousness noisy, rattling breathing numbness or tingling in the arms or legs pounding in the ears shortness of breath swelling of the fingers, hands, feet, or lower legs trouble thinking, speaking, or walking troubled breathing at rest weight gain Incidence not known Abdominal cramping and/or burning (severe) abdominal pain backache bloody, black, or tarry stools cough or hoarseness darkening of skin decrease in height decreased vision diarrhea dry mouth eye pain eye tearing facial hair growth in females fainting fatigue fever or chills flushed, dry skin fractures fruit-like breath odor full or round face, neck, or trunk heartburn and/or indigestion (severe and continuous) increased hunger increased thirst increased urination loss of appetite loss of sexual desire or ability lower back or side pain menstrual irregularities muscle pain or tenderness muscle wasting or weakness nausea pain in back, ribs, arms, or legs painful or difficult urination skin rash sleeplessness sweating trouble healing trouble sleeping unexplained weight loss unusual tiredness or weakness vision changes vomiting vomiting of material that looks like coffee grounds
Some side effects of methylprednisolone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common Increased appetite Incidence not known Abnormal fat deposits on the face, neck, and trunk acne dry scalp lightening of normal skin color red face reddish purple lines on the arms, face, legs, trunk, or groin swelling of the stomach area thinning of the scalp hair For Healthcare Professionals
Applies to methylprednisolone: compounding powder, injectable powder for injection, injectable suspension, oral tablet
General Adverse effects have occurred less frequently when minimum dosages have been administered.
Adverse effects of corticosteroid therapy may be subdivided into those associated with short-term therapy (to three weeks) and those of long-term therapy (> three weeks).
Short-term effects have included sodium retention-related weight gain and fluid accumulation, hyperglycemia and glucose intolerance, hypokalemia, gastrointestinal upset and ulceration, reversible depression of the hypothalamic-pituitary-adrenal (HPA) axis, and mood changes ranging from mild euphoria and insomnia to nervousness, restlessness, mania, catatonia, depression, delusions, hallucinations, and violent behavior.
Long-term effects have included HPA suppression, Cushingoid appearance, hirsutism or virilism, impotence, and menstrual irregularities, peptic ulcer disease, cataracts and increased intraocular pressure/glaucoma, myopathy, osteoporosis, and vertebral compression fractures.
Cardiovascular Cardiovascular side effects have included hypertension and congestive heart failure due to long-term fluid retention as well as direct vascular effects. Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, fat embolism, myocardial rupture following recent myocardial infarction, syncope, tachycardia, thromboembolism, thrombophlebitis, and vasculitis have also been reported.
Hypertension has been associated with long-term therapy with corticosteroids and is thought to be due to fluid retention.
Endocrine Corticosteroid therapy may induce glucose intolerance by reducing the utilization of glucose in tissues and increasing hepatic glucose output. Patients on alternate day therapy may exhibit significantly higher serum glucose on the day methylprednisolone is taken. Diabetes mellitus requiring diet modifications and hypoglycemic agents has developed in some patients.
Adrenal Adrenal suppression can persist for up to twelve months after long-term corticosteroid therapy. Adrenal suppression may be reduced by giving corticosteroids once a day or once every other day. After corticosteroid therapy has been tapered, supplemental corticosteroid therapy during times of physical stress may be required.
Endocrine side effects have included decreased glucose tolerance and hyperglycemia resulting in diabetes-like symptoms. Hypothalamic-pituitary-adrenal activity has been suppressed 12 months or more following long-term corticosteroid administration. Cushingoid appearance commonly has occurred with chronic therapy. Hirsutism or virilism, impotence, and menstrualirregularities may occur. Glycosuria, hirsutism, and hypertrichosis have also been reported.
Gastrointestinal Gastrointestinal side effects have included gastrointestinal upset, nausea, vomiting, and peptic ulcer disease. Pancreatitis, ulcerative esophagitis, gastrointestinal perforation and hemorrhage have also been reported. Additionally, abdominal distention, bowel/bladder dysfunction (after intrathecal administration), increased appetite, and perforation of the small and large intestine (particularly in patients with inflammatory bowel disease) have been reported.
Gastrointestinal effects most commonly occurring during corticosteroid therapy have included nausea, vomiting, dyspepsia, and anorexia. Peptic ulcer disease has been associated with long-term corticosteroid therapy, but is relatively uncommon. Routine prophylactic therapy is not warranted in all individuals. Aluminum/magnesium containing antacids generally have been used to manage GI complaints without significant drug interactions.
Metabolic Metabolic side effects have included hypernatremia (rare), hypokalemia, fluid retention, negative nitrogen balance and increase in blood urea nitrogen concentration.
Musculoskeletal Musculoskeletal side effects have included myopathy, osteoporosis, vertebral compression fractures, tendon rupture (particularly the Achilles tendon), and aseptic necrosis of bone have occurred during corticosteroid therapy. Aseptic necrosis most often has affected the femoral head. Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, and vertebral compression fractures has also been reported.
Corticosteroid myopathy presenting as weakness and wasting of the proximal limb and girdle muscles has occurred, but has generally resolved following cessation of therapy.
Corticosteroids inhibit intestinal absorption and increase urinary excretion of calcium leading to bone resorption and bone loss. Bone loss of 3% over one year has been demonstrated with prednisolone 10 mg per day. Postmenopausal females are at risk of loss of bone density. Up to 16% of elderly patients treated with corticosteroids for 5 years may experience vertebral compression fractures. One author reported measurable bone loss over two years in women on concomitant therapy with prednisone 7.5 mg per day and tamoxifen.
Hematologic Hematologic side effects have included thrombocytopenia, lymphopenia, and platelet alterations resulting in thrombolic events.
Immunologic Immunologic side effects have included impairment in cell-mediated immunity and increased susceptibility to bacterial, viral, fungal and parasitic infections. Immune response to skin tests may be suppressed.
Hepatic Hepatic side effects have included reversible increases in serum transaminase and alkaline phosphatase concentrations. Hepatomegaly has also bee reported.
Ocular In renal transplant patients maintained on prednisone 10 mg per day, 33% developed posterior subcapsular cataracts. Mean time to cataract development was 26 months. Increased intraocular pressure has occurred in 5% of patients.
Ocular side effects have included increased intraocular pressure, glaucoma, and posterior subcapsular cataracts.
Psychiatric Psychiatric side effects have included psychoses, personality or behavioral changes, depression, emotional instability, euphoria, mood swings, and psychic disorders.
Dermatologic Dermatologic side effects have included bruising, ecchymosis, petechiae striae, delayed wound healing, and acne. Allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, erythema, hyperpigmentation, hypopigmentation, increase sweating, rash, sterile abscess, striae, thin fragile skin, and thinning scalp hair, and urticaria have also been reported.
Other Other side effects have included a glucocorticoid withdrawal syndrome seen upon abrupt discontinuation of corticosteroid therapy that was not associated with adrenal suppression.
Pseudorheumatism, or glucocorticoid-withdrawal syndrome not related to adrenal insufficiency has occurred on withdrawal of corticosteroids. Patients experienced anorexia, nausea, vomiting, lethargy, headache, fever, arthralgias, myalgias and postural hypotension. Symptoms resolved when corticosteroid therapy was reinstated.
Oncologic Oncologic side effects have included Kaposi's sarcoma. Clinical remission may occur with discontinuation of therapy.
Hypersensitivity Hypersensitivity side effects have included anaphylaxis with or without circulatory collapse, cardiac arrest, or bronchospasm with parenteral administration of methylprednisolone. Anaphylactoid reactions and angioedema have also been reported.
Local Local side effects have included hyperpigmentation, hypopigmentation, subcutaneous and cutaneous atrophy, and sterile abscess at injection sites following parenteral administration.
Respiratory Respiratory side effects have included pulmonary edema.
Nervous system Nervous system side effects have included convulsions, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, neuritis, neuropathy, paresthesia, and vertigo.
News 
Market Data 
Discover 
